Ecallantide: Difference between revisions
Kurtucla05 (talk | contribs) (Created page with "==General== *Type: Kallikrein inhibitor for angioedema *Dosage Forms: 30mg *Routes of Administration: SQ *Common Trade Names: Kalbitor ==Adult Dosing== *30mg SQ *Max 60mg/ 2...") |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Acute hereditary angioedema]]=== | |||
*30mg SQ | *30mg SQ | ||
*Max 60mg/ 24 hr | *Max 60mg/ 24 hr | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===[[Acute hereditary angioedema]] (>12yo)=== | |||
*30mg SQ | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | ||
| Line 29: | Line 32: | ||
*diarrhea | *diarrhea | ||
*URI | *URI | ||
*injection site | *injection site reaction | ||
*nasopharyngitis | *nasopharyngitis | ||
*vomiting | *vomiting | ||
| Line 50: | Line 53: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 16:07, 17 August 2019
General
- Type: Kallikrein inhibitor for angioedema
- Dosage Forms: 30mg
- Routes of Administration: SQ
- Common Trade Names: Kalbitor
Adult Dosing
Acute hereditary angioedema
- 30mg SQ
- Max 60mg/ 24 hr
Pediatric Dosing
Acute hereditary angioedema (>12yo)
- 30mg SQ
Special Populations
- Pregnancy Rating:C
- Lactation risk:Safety Unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- hypersensitivity reaction
Common
- headache
- nausea
- fatigue
- diarrhea
- URI
- injection site reaction
- nasopharyngitis
- vomiting
- pruritus
- abdominal pain
- fever
- anaphylaxis
Pharmacology
- Half-life: 2h
- Metabolism: CYP450
- Excretion: Urine
- Mechanism of Action: selectively, reversibly inhibits plasma kallikrein, preventing bradykinin generation
Comments
- Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema